TIRZEPATIDE (Mounjaro®)

Clinical Indication

Management of overweight and obesity

Comments

January 2025: Tirzepatide should NOT be prescribed for managing overweight and obesity. 
Whilst NICE TA1026 was published in December 2024, the ICB awaits further commissioning guidance from NHS England. Further details about local implementation will be provided in due course. Until that time, tirzepatide should not be prescribed for this indication.

Date of classification

January 2025

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.